Author: admin

Keratoconus Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | CooperVision, Optik Seis, SAFILENS S.R.L, Novartis, CIBA VISION, Menicon, Bausch & Lomb

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Keratoconus pipeline constitutes 3+ key companies continuously working towards developing 3+ Keratoconus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Keratoconus Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Keratoconus Market.

 

The Keratoconus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Keratoconus Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Keratoconus treatment therapies with a considerable amount of success over the years.

  • Keratoconus companies working in the treatment market are Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others, are developing therapies for the Keratoconus treatment

  • Emerging Keratoconus therapies in the different phases of clinical trials are- Riboflavin 5′-Phosphate, IVMED-80, Dextenza, and others are expected to have a significant impact on the Keratoconus market in the coming years.

  • In December 2024, Glaukos Corporation (NYSE: GKOS), a pharmaceutical and medical technology company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases, submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on). This next-generation corneal cross-linking iLink therapy is designed for the treatment of keratoconus, a progressive and sight-threatening corneal disease.

 

Keratoconus Overview

Keratoconus is a progressive eye disease in which the normally round, dome-shaped cornea thins and begins to bulge into a cone-like shape. This cone shape deflects light as it enters the eye, causing distorted vision.

 

Get a Free Sample PDF Report to know more about Keratoconus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/keratoconus-pipeline-insight

 

Emerging Keratoconus Drugs Under Different Phases of Clinical Development Include:

  • Riboflavin 5′-Phosphate: Glaukos Corporation

  • IVMED-80: iVeena Delivery Systems

  • Dextenza: Ocular Therapeutix, Inc.

 

Keratoconus Route of Administration

Keratoconus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Keratoconus Molecule Type

Keratoconus Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Keratoconus Pipeline Therapeutics Assessment

  • Keratoconus Assessment by Product Type

  • Keratoconus By Stage and Product Type

  • Keratoconus Assessment by Route of Administration

  • Keratoconus By Stage and Route of Administration

  • Keratoconus Assessment by Molecule Type

  • Keratoconus by Stage and Molecule Type

 

DelveInsight’s Keratoconus Report covers around 3v+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Keratoconus product details are provided in the report. Download the Keratoconus pipeline report to learn more about the emerging Keratoconus therapies

 

Some of the key companies in the Keratoconus Therapeutics Market include:

Key companies developing therapies for Keratoconus are – CooperVision, Optik Seis, SAFILENS S.R.L, Novartis AG, CIBA VISION, Menicon Co. Ltd, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care Inc, HOYA Vision Care, and others.

 

Keratoconus Pipeline Analysis:

The Keratoconus pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Keratoconus with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Keratoconus Treatment.

  • Keratoconus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Keratoconus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Keratoconus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Keratoconus drugs and therapies

 

Keratoconus Pipeline Market Strengths

  • Environmental factors contribute to the wide variation in prevalence. Geographical locations with plenty of sunshine and hot weather have a higher prevalence than locations with colder climates and less sunlight

 

Keratoconus Pipeline Market Opportunities

  • There is limited approved therapy for Keratoconus, which opens up a huge platform of new therapies to boon the market.

 

Scope of Keratoconus Pipeline Drug Insight

  • Coverage: Global

  • Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others

  • Key Keratoconus Therapies: Riboflavin 5′-Phosphate, IVMED-80, Dextenza, and others

  • Keratoconus Therapeutic Assessment: Keratoconus current marketed and Keratoconus emerging therapies

  • Keratoconus Market Dynamics: Keratoconus market drivers and Keratoconus market barriers

 

Request for Sample PDF Report for Keratoconus Pipeline Assessment and clinical trials

 

Table of Contents

1. Keratoconus Report Introduction

2. Keratoconus Executive Summary

3. Keratoconus Overview

4. Keratoconus- Analytical Perspective In-depth Commercial Assessment

5. Keratoconus Pipeline Therapeutics

6. Keratoconus Late Stage Products (Phase II/III)

7. Keratoconus Mid Stage Products (Phase II)

8. Keratoconus Early Stage Products (Phase I)

9. Keratoconus Preclinical Stage Products

10. Keratoconus Therapeutics Assessment

11. Keratoconus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Keratoconus Key Companies

14. Keratoconus Key Products

15. Keratoconus Unmet Needs

16 . Keratoconus Market Drivers and Barriers

17. Keratoconus Future Perspectives and Conclusion

18. Keratoconus Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Keratoconus Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | CooperVision, Optik Seis, SAFILENS S.R.L, Novartis, CIBA VISION, Menicon, Bausch & Lomb

Beyond Code, It’s the Universe – Envo CTO Shares Vision for Web3 Evolution in Recent Dialogue Event

In a recent dialogue event, Envo’s Chief Technology Officer (CTO) shared insights into the platform’s foundational logic, product evolution, future roadmap, and driving principles, providing a compelling glimpse into one of Web3’s most ambitious projects. As Web3 progresses beyond hype into real-world applications, only a select few platforms have demonstrated the systematic capability to scale, innovate, and define the future. Envo has distinguished itself through continuous product innovation and ecosystem expansion, setting new benchmarks in user experience, tokenomics, and technical infrastructure.

Envo has consistently pushed industry boundaries over the past two years, earning the nickname “iOS of the Web3 world” for offering a comprehensive ecosystem with exceptional user experience. However, the CTO asserts that Envo’s ambition surpasses this comparison. Unlike iOS, which operates as a closed system, Envo aims to build an “open protocol for digital civilization.” Its architecture is based on three pillars: blockchain trustworthiness, AI intelligence, and the real-time nature of edge computing. In social settings, dynamic user-generated content is rendered in real-time with particle effects through distributed nodes, while the AI engine optimizes the loading path. This technological fusion enables Web3 experiences to match the fluidity of traditional internet services. Rather than following industry standards, Envo seeks to define them.

The Envo ecosystem spans multiple domains, including payments, gaming, and AI. Its expansion is strategic, aimed at constructing the “foundation of digital civilization.” In the payment sector, Envo partners with leading financial institutions to leverage blockchain transparency and smart contract automation, improving traditional financial compliance efficiency by 80%. In gaming, the open-sourced physics engine toolkit attracts developers to build content on Envo’s underlying protocols, creating a “technology supply – ecosystem feedback” loop. Standardized interfaces interconnect modules, sharing user and data resources, ultimately driving exponential growth.

Critics argue that Web3 users prioritize asset yields over technological breakthroughs. However, the CTO identifies this as a cognitive trap within the industry. Web3 must transcend the speculative phase of DeFi Summer. Envo’s user data indicates that when technology creates real value, rewards naturally follow. Technology serves as the engine of value creation rather than the end goal.

The DND token’s stability during the bear market has raised questions about the sustainability of its deflationary model. The CTO explains that DND follows a “value anchoring” principle. Smart contract destruction mechanisms allocate a portion of the platform’s revenue to buy back and burn tokens, ensuring deflation. Simultaneously, DND is deeply integrated into the ecosystem, allowing holders to stake tokens for DAO governance votes or redeem exclusive AI toolkits. Future plans include a “proof of contribution” mechanism, enabling users to earn DND by participating in ecosystem development, further strengthening the symbiotic relationship between the token and the platform.

Rumors suggest that Envo will launch its own exchange, signaling potential entry into the DeFi market. The CTO clarifies that Envo is developing the first community-driven Web3 exchange. This exchange will not mimic platforms like Uniswap or Binance; instead, it will operate as a protocol layer governed entirely by the community. DND holders will vote on listing rules, and market maker roles will be open to those with sufficient credibility ratings. Additionally, the exchange will integrate with Envo’s existing ecosystem, where social status within Envo may translate to discounted trading fees. The launch is expected in the second half of the year.

Envo’s ultimate goal is to establish Web3 as foundational infrastructure for digital civilization, accessible to everyone. Whether it is an African developer creating a hit blockchain game in three days or an overseas student forming a cross-border DAO organization using Envo’s meeting system, these moments demonstrate technology’s power to empower individuals to change the world.

In this 45-minute discussion, the Envo CTO showcased the same disruptive qualities as the technology itself—combining ambition with grounded logic. When questioned about the risk of imitation, the CTO confidently noted, “Imitators will always chase yesterday, while our code is always compiling tomorrow.

More info: https://twitter.com/Envo_Official

Disclaimer: This press release may contain certain forward-looking statements. Forward-looking statements describe expectations, plans, outcomes, or strategies for the future (including product offerings, regulatory plans, and business plans) and are subject to change without prior notice. Please be advised that such statements are influenced by various uncertainties, which may result in future circumstances, events, or outcomes differing from those predicted in the forward-looking statements.

Media Contact
Company Name: HOLDWIN INTERNATIONAL PTE. LTD
Contact Person: Hank
Email: Send Email
Country: Singapore
Website: http://envo.social/

GCC: Bridging Web 2.0 and Web 3.0 to Make Blockchain Accessible to All

The rapid evolution of blockchain technology has ushered in a decentralized era, yet the transition from Web 2.0 to Web 3.0 remains fraught with challenges. Global Coin Chain (GCC) addresses this through a four-dimensional innovation system — integrating an airdrop fission ecosystem, an AI development engine, cross-chain interoperability, and a Gas payment revolution — to create a seamless bridge for users and developers into the Web3 world.

1. Airdrop Fission: Redefining User Growth

In the Web 2.0 era, user acquisition relied heavily on centralized platforms’ traffic distribution mechanisms. GCC revolutionizes this model by leveraging deep integration with Telegram to build an airdrop fission ecosystem centered on its Airdrop Traffic (ADT) engine. This system transforms user behavior into a source of value creation, establishing a novel paradigm for user growth.

Within ADT, users earn airdrops or token rewards through interactive actions such as completing tasks, participating in games, or social sharing. This mechanism empowers users with value-creation opportunities, significantly boosting engagement.

Crucially, GCC introduces a dual deflationary model: User interactions trigger token burns, effectively controlling circulating supply.Token lock-up mechanisms ensure orderly liquidity release, preventing market volatility caused by excessive circulation.

This design avoids hyperinflation while incentivizing long-term participation through time-value leverage, creating a “participation-as-investment” dynamic. The result is a virtuous cycle of user growth and value accumulation, positioning ADT as a key driver of Web3-era expansion.

2. AI Development Engine: Unleashing On-Chain Creativity

Blockchain innovation has long been constrained by high technical barriers. GCC’s AI Smart Contract Generator breaks this bottleneck: developers input requirements in natural language, and the AI instantly generates secure, executable code.

This “Think-to-Code” experience democratizes smart contract creation, shifting innovation from professional coders to broader communities. Teams focus on core functionality rather than coding complexities, slashing development cycles and costs.

For traditional enterprises, GCC’s API integration framework unlocks Web3 potential. Businesses can complete blockchain integration in as little as one week, enabling rapid entry into the trillion-dollar Web3 market. This transformative capability positions GCC as a bridge for enterprises to ride the blockchain wave and lead global digital transformation.

3. Cross-Chain Interoperability: Building the Value Internet

Blockchain’s “island effect” — the isolation between networks — has stifled ecosystem synergy. GCC’s decentralized oracle layer (DOL) shatters these barriers, enabling second-chain asset transfers and forging a true value internet.

When assets flow freely across chains, value discovery accelerates exponentially. Innovations like cross-chain liquidity mining and lending will flourish, reshaping the depth and breadth of the crypto economy while unlocking unprecedented opportunities for users and developers.

4. Gas Payment Revolution: Reinventing Transactional UX

Traditional Gas fee mechanisms have long been a barrier to blockchain adoption. GCC’s innovative solution returns payment autonomy to users: Pay with any token: Users choose their preferred currency for transaction fees. Smart fee estimation: Real-time cost optimization eliminates Gas anxiety.

This frictionless design enhances user retention, builds trust, and unifies the fragmented crypto economy. By unifying cross-chain transaction costs, GCC erases economic fragmentation, enabling seamless value circulation and laying the foundation for large-scale commercial adoption.

Conclusion

GCC’s four-dimensional innovation system is not merely a collection of isolated features but an interconnected ecosystem. From user acquisition to dApp development, value flow to transaction experiences, every component embodies the “zero-barrier” philosophy. As technical hurdles dissolve, GCC will empower billions of Web 2.0 users to embrace Web3, catalyzing a new paradigm of decentralized digital economy.

Contact Us:

Website：https://g.cc/

GCC X：https://x.com/GCC_Airdrop

ADT Airdrop： adt.g.cc

ADT Telegram Grop：https://t.me/GCC_Airdrop

ADT Telegram_bot：https://t.me/GccAirdrop_bot

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Global Coin Chain
Contact Person: Lyon
Email: Send Email
Country: United States
Website: https://g.cc/

Powerful Performance, Perfect Gift for Art Lovers: Introducing Fun Drawing Pad UT2 by ugee

The ugee Fun Drawing Pad UT2 might appear charming enough at first glance, but there’s a certain charm that reveals itself once the stylus glides across the canvas. This Android 14-powered tablet is poised to become the ideal tool and a perfect gift for art lovers. After all, who wouldn’t want to embark on a creative adventure with something that overflows boundless enjoyment?

At the heart of the Fun Drawing Pad UT2 lies the Android 14, optimized to deliver exceptional speed, robust security, and versatile functionality. Art lovers are granted access to various ecosystems of applications tailored for creative expression. Multitasking also becomes effortless with the aid of a 6nm 8-core processor, ensuring the creative sessions are both productive and uninterrupted. The combination of this refined operating system and powerful hardware renders the UT2 an indispensable gift for art lovers who seek a reliable and feature-rich tool.

With its NanoMatte finish featuring an anti-glare and paper-like screen, the UT2 tries to blur the dividing line between traditional and digital arts. Even if those are just dipping toes into this artistic domain, it will still make one feel similar to drawing on real paper.

A stunning canvas deserves a matchable stylus. This U-Pencil is tailored for it and included in the package. The specifications such as 4096-level pressure sensitivity, 20ms latency, ±0.5mm accuracy, and 10g initial activation force may sound technical, while all of these are pointed to the precise and nuanced strokes that respond to even the slightest touch to firmer press, and delegating full control over the flow of each line. Its comfy and lightweight grip is sure to render the pencil-on-paper experience.

This pad is born with a 16:10 superb ratio for holding in hand and following the wrist movements, serving as the 10.36-inch 2K canvas to render everyone an immersive artistic experience. Featuring a color gamut of NTSC>72% and a palette of 16.7 million colors, the canvas ensures no hue goes unnoticed.

It is also lightweight and portable. Weighing only 466g, the carry-on palette allows one to capture the inspiration anywhere one goes and anytime it comes. From capturing vibrant landscapes outdoors to refining intricate details while bent over the table, it stands here on the artistic experiment with different styles in various settings.

For those just embarking on their artistic journey or seeking a reliable tool to enhance their creative skills, the UT2 is sure to be the perfect gift for those art lovers. Stylus, smart folio, gloves, nibs and more essentials are all included in the package without extra expense. With its seamless performance, pencil-on-paper experience, and generous canvas, it ensures that the artistic expression knows no boundaries. The ugee Fun Drawing Pad UT2 proves that the right tool can make all the difference.

Media Contact
Company Name: Hanvon Ugee Technology Co., Ltd.
Contact Person: Rita Zhao
Email: Send Email
Country: China
Website: ugee.com

New Business Podcast The Founder’s Club Set To Explode

Each year more than four hundred thousand businesses are started in Australia but sadly, 20% of new businesses will fail in the first year and 60% within three years. Thankfully, a successful business expert who is the founder of Live Good Digital, a digital marketing agency is looking to help more people succeed.

Emily Jean who knows the pitfalls of starting a new business wants to help more people succeed and wants to help younger people to become a success in business.

The founder of Live Good Digital has started a new podcast called The Founder’s Club which aims to help people to become a success. Before I interviewed Emily Jean, she told me on the phone that she was passionate about helping entrepreneurs and business leaders build meaningful, successful businesses that allow them to live good lives. When I sat down with her, it was obvious how passionate she was.

The Founder’s Club podcast which can be listened to on all major problems is set to be a huge success. This is what Emily had to say when I sat down with her.

You have a podcast called the Founder’s Club, can you tell me what the podcast is about?

The Founder’s Club is all about sharing real, engaging stories from entrepreneurs at every stage of their journey. We discuss not just their successes, but also their struggles and the valuable lessons learned along the way. It’s an authentic, transparent look at entrepreneurship.

Who is your podcast aimed at and what age group do you expect to attract?

Our podcast primarily attracts young adults and aspiring entrepreneurs, generally aged between 18 to 35, who are curious about entrepreneurship or already running their own businesses.

You say that your podcast is going to be full of founders and entrepreneurs, can you give me some examples?

Absolutely! We feature diverse entrepreneurs, from small family-run businesses to founders of multimillion-dollar companies. We’ve had guests from industries like beauty and skincare, fashion, AI, health tech, and even home decor. Each guest brings a unique perspective to the table.

The COVID pandemic affected businesses around the world. It resulted in millions of businesses collapsing, but it also resulted in a lot of people starting their own business. Why do you think the COVID pandemic encouraged more people to start their own business?

COVID created an environment of necessity and opportunity. People found themselves reflecting deeply on their life and career paths. Many realized they wanted more flexibility, meaning, and control over their professional lives, leading to a boom in entrepreneurship.

Will you podcast talk about motivation to start a business and do you believe that people who listen to your podcast will be motivated to start their business?

Yes, motivation is central to our podcast. By sharing authentic, inspiring stories from successful founders, listeners are not only motivated but also equipped with actionable advice to confidently start or grow their own ventures.

What do you believe is the biggest stumbling point in a person starting a business?

I believe the biggest stumbling block is often the fear of failure or uncertainty about how to start. Many potential entrepreneurs are held back because they worry about making mistakes or fear financial instability. Our goal is to ease those fears by sharing relatable experiences and practical advice.

One of the biggest challenges a person has when thinking about starting their own business is funding. Banks have become very strict on who they will and will not lend money to. So, if banks are no longer an option for funding, what other funding sources are available?

Entrepreneurs can explore alternatives like crowdfunding, angel investors, venture capital, grants, peer-to-peer lending, and even bootstrapping—using personal savings or resources from friends and family. There are many creative ways to finance a business today.

You are having an exclusive launch party, can you tell me more about that?

We’re thrilled to mark the launch of The Founder’s Club with an exclusive event that will feature networking opportunities, engaging conversations with inspiring guests, and meaningful connections between listeners and entrepreneurs. It’s truly a celebration of entrepreneurship and community, hosted at Scape Redfern in Sydney. Scape aligns perfectly with our vision of nurturing future leaders, thanks to their consistent commitment to cultivating talent and innovation. We couldn’t imagine a better venue to celebrate our launch!

There are many podcasts out there; what makes your podcast stand out? The authenticity and diversity of our guests truly make The Founder’s Club unique. We’re committed to providing transparent, inspiring conversations—not sales pitches. Our guests include founders from well-loved brands who share real, relatable stories and actionable insights.

You say you are going to cover inspiring stories that resonate with anyone looking to innovate and succeed, but are you also going to be talking about the pitfalls and mistakes that people have made starting their own business?

Will you discuss the pitfalls and mistakes entrepreneurs have faced? Absolutely. Discussing pitfalls and mistakes is crucial, as they provide powerful lessons and reassurance that challenges are normal and part of the entrepreneurial journey.

You aim to help young people become entrepreneurs. How old were you when you became interested in business, and when did you start your first business?

I developed a passion for entrepreneurship quite young, about 14 when I graduated from high-school early to pursue a different path. However, I only formally stepped into the entrepreneurial world when I launched Live Good Digital last year. It was driven by a desire to help others achieve a healthier work-life balance and find fulfilment through their businesses.

Do you think schools should do more to encourage young people to become entrepreneurs? Definitely. Entrepreneurship education in schools would empower young people with critical thinking, creativity, and problem-solving skills. Schools could better equip students with practical tools and confidence to innovate and succeed in the real world.

How often will the podcast be broadcast, and where can people listen? New episodes are released weekly, every Monday. You can find The Founder’s Club on all major podcast platforms, including Spotify, Apple Podcasts, and Google Podcasts. We’re so excited for listeners to tune in!

Listen to the Podcast here: https://open.spotify.com/show/3kiqSke5mnlFIlC9t4xLU0?si=19b812aa43f442dc

And here:

https://podcasts.apple.com/us/podcast/founders-club/id1802430594

Media Contact
Company Name: Live Good Digital
Contact Person: Rita Williams
Email: Send Email
Country: Australia
Website: https://www.livegooddigital.com/

Russian Teacher Olesia: Devoted to Beautiful Mountain City and Sino-Russian Education Cooperation

Olesia (Full name Topko Olesia) from Moscow State University of Technology “STANKIN” in Russia is currently teaching Russian in the International School of Intelligent Manufacturing of Chongqing Vocational Institute of Engineering (CQVIE).

Olesia is teaching students

In May 2023, Olesia first arrived in Chongqing. She praised the school’s landscape and natural scenery that blended the design of mountains and water upon her arrival at CQVIE. During her spare time, she visited many areas nearby. According to her observations, Chongqing is a metropolis with strong modernity. The city’s public transportation system is highly developed, with convenient access to subways, buses, and taxis, allowing effortless exploration of every scenic attraction.

Olesia favorite way to understand Chongqing’s essence is through exploring its urban parks and museums, where she delves into the mountain city’s unique landscape and profound cultural heritage. The city’s three-dimensional urban layout particularly fascinates her, with iconic landmarks like the “LRT-through-building” at Liziba Station, the panoramic “Eye in the Sky” observatory, and the dazzling nightscape of Hongyadong, all embodying the “8D spatial magic” that blends futuristic urban planning with vibrant street life. This harmonious coexistence of architectural wonder and humanistic vitality forms Chongqing’s distinctive aesthetic charm. ‌

When discussing her teaching philosophy, Olesia highlights Russian’s unique linguistic charm and profound cultural richness that captivate language enthusiasts worldwide‌. However, the language’s tricky pronunciation, intricate grammatical cases, and labyrinthine verb conjugations often create psychological barriers for Chinese learners during their studies‌. For her, teaching Russian to Chinese students is more challenging.

Olesia is teaching students

To help students release stress, Olesia emphasizes interaction in teaching. She often teaches Russian with examples, such as books, stationery and daily necessities to stimulate students’ interest in learning, help them master the key points and improve their practical use of Russian. At the same time, Olesia incorporates unique Russian culture, customs and history into her language teaching, allowing students to better understand the traditional Russian culture as well as the language points. In her dedicated guidance, students has made rapid progress in Russian proficiency and significantly improved their cross-cultural communication skills.

In March 2022, the Sino-foreign cooperative education institution established by Chongqing Vocational Institute of Engineering (CQVIE) and Moscow State University of Technology “STANKIN”, the CQVIE International Institute of Intelligent Manufacturing, obtained official approval from China’s Ministry of Education. In March 2025, CQVIE and STANKIN further solidified their partnership by signing an educational and scientific cooperation agreement to jointly establish the China-Russia Innovation Development Center. As cooperation deepens, Olesia envisions her students mastering language skills to become cultural envoys, channeling youthful energy into advancing international exchanges and technological collaboration.

(Pictures provided by interviewee)

Media Contact
Company Name: CQVIE
Contact Person: Bing Luo
Email: Send Email
City: Chongqing
Country: China
Website: https://www.cqvie.edu.cn/

Malignant Pleural Effusion Market Across the 7MM to Witness Promising Growth Through 2034 | DelveInsight

Leading Malignant Pleural Effusion companies in the market include – RS Oncology, Genelux Corporation, Candel Therapeutics, and others.

 

The Malignant Pleural Effusion Market is projected to experience steady growth at a decent CAGR through 2034 The malignant pleural effusion landscape is currently characterized by the absence of approved pharmacological interventions, with traditional drainage procedures dominating treatment approaches. This creates significant opportunities for pharmaceutical innovators to address unmet needs in this oncological complication which affects thousands of cancer patients worldwide. Key companies advancing therapeutic solutions in this area include RS Oncology, Genelux Corporation, and Candel Therapeutics, among others, with some promising candidates progressing through various stages of clinical development.

 

DelveInsight’s “Malignant Pleural Effusion Market Insight, Epidemiology and Market Forecast 2034“ report provides a detailed analysis of market trends, epidemiological patterns, and therapeutic development across the 7MM. The United States represents the largest segment of the malignant pleural effusion market, accounting for approximately 38% of incident cases within the analyzed regions. Among European countries, Among European countries, Germany has the highest proportion of diagnosed cases, while Spain has the lowest share of diagnosed cases.

 

Download the malignant pleural effusion market report to understand which factors are driving the malignant pleural effusion therapeutic market @ Malignant Pleural Effusion Market Trends

 

Among total malignant pleural effusion incident cases in the US, approximately 75% receive a formal diagnosis, while 25% remain undetected. When analyzed by tumor type, lung cancer leads to the highest incidence of malignant pleural effusion, responsible for around 30% of total cases attributed to this cancer type in 2023 across the 7MM.

 

The report also examines the current and emerging malignant pleural effusion treatment landscape. At present, the market lacks approved pharmacological interventions specifically targeting this condition, with drainage procedures considered the standard of care across treatment centers.

 

Discover evolving trends in the malignant pleural effusion treatment landscape @ Malignant Pleural Effusion Therapeutics Market

 

Malignant pleural effusion occurs when fluid containing cancer cells accumulates between the chest wall and the lung, resulting in symptoms such as difficulty breathing and chest discomfort. Current diagnostic approaches include cytological examination of fluid samples, histological assessment of tissue biopsies, and advanced imaging techniques like ultrasound, computed tomography, PET scans, and thoracoscopy.

 

Current treatment approaches focus primarily on symptom management rather than targeted modification of the disease. Therapeutic strategies usually involve conservative methods including repeated thoracentesis, pleurodesis, or the placement of indwelling pleural catheters. Additional interventions may include chemotherapy, radiation therapy, or the direct administration of medication to the pleural space, with sclerosing agents sometimes used in recurrent cases to induce pleural fibrosis and prevent fluid reaccumulation.

 

In early March 2025, the American Society of Clinical Oncology (ASCO) released updated guidelines for the treatment of malignant pleural mesothelioma. These updated guidelines emphasize a more nuanced approach to surgery, integration of immunotherapy, importance of genetic testing, and refined pathologic insights

 

Although the therapeutic pipeline for malignant pleural effusion is relatively limited, there have been some promising advancements. In September 2024, the U.S. FDA approved KEYTRUDA (Merck) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma. Additionally, RS Oncology launched a Phase II dose expansion in the MITOPE study for RSO-021 in February 2024. Other companies with potential interest in this therapeutic area include Genelux Corporation and Candel Therapeutics. The scarcity in the therapeutic pipeline offers substantial opportunities for pharmaceutical companies willing to invest in this area.

 

Unlock which malignant pleural effusion drug is expected to capture the largest market share in 7MM by 2034. Visit the Malignant Pleural Effusion Market Insights

 

DelveInsight’s report underscores that the limited number of companies engaging in this therapeutic area could significantly impact future market dynamics. RS Oncology’s progress through clinical trials may attract interest from larger pharmaceutical companies, potentially transforming the malignant pleural effusion therapeutic landscape in the coming years. The report also highlights that effectively addressing this condition requires a balance between providing symptomatic relief and implementing targeted approaches to manage the underlying malignancy, presenting both challenges and opportunities for stakeholders in this evolving treatment space.

 

Table of Contents

1

Key Insights

2

Report Introduction

3

Malignant Pleural Effusion Market Overview at a Glance

4

Executive Summary of Malignant Pleural Effusion

5

Epidemiology and Market Methodology

6

Disease Background and Overview

7

Malignant Pleural Effusion Diagnosis

8

Malignant Pleural Effusion Treatment

9

Conclusion

10

Malignant Pleural Effusion Epidemiology and Patient Population

11

Malignant Pleural Effusion Patient Journey

12

Key Endpoints in Malignant Pleural Effusion Clinical Trials

13

Malignant Pleural Effusion Emerging Therapies

14

Malignant Pleural Effusion: 7 Major Market Analysis

15

KOL Views

16

SWOT Analysis

17

Malignant Pleural Effusion Unmet Needs

18

Appendix

19

DelveInsight Capabilities

20

Disclaimer

21

About DelveInsight

 

Related Reports

Malignant Pleural Effusion Pipeline Insights

Malignant Pleural Effusion Pipeline Insight provides comprehensive insights about the Malignant Pleural Effusion pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Malignant Pleural Effusion companies, including LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Merk, and Simcere Pharmaceutical Group among others.

 

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Malignant Pleural Effusion Market Across the 7MM to Witness Promising Growth Through 2034 | DelveInsight

Introducing The Founder’s Club Podcast: A New Voice in the World of Entrepreneurship

Emily Jean, the innovative founder of Live Good Digital and a seasoned digital marketing expert, is thrilled to announce the launch of her latest venture, the Founder’s Club podcast. This new podcast aims to empower and inspire the next generation of entrepreneurs by sharing authentic stories from business leaders across the globe. With an emphasis on both triumphs and trials, Founder’s Club delves into the real-life experiences of entrepreneurs, providing invaluable insights for budding business minds.

The Founder’s Club podcast represents Jean’s passion for helping entrepreneurs create meaningful and successful businesses while also enjoying life to the fullest. Through candid, engaging discussions with guests who have navigated the highs and lows of entrepreneurship, the podcast offers a transparent look into what it truly takes to build a successful business. Listeners can expect to hear stories of both the struggle and success, with each episode delivering practical lessons and inspiration.

“We want to peel back the layers and expose the unvarnished truth of entrepreneurship,” said Emily Jean. “Our goal is to offer listeners an authentic understanding of the business world, by sharing the stories of those who’ve been there and done it. We believe that these genuine insights will guide and motivate aspiring entrepreneurs to carve their own paths successfully.”

The Founder’s Club targets young adults and aspiring entrepreneurs, particularly between the ages of 18 to 35, who are eager to learn about starting and running their own businesses. This demographic is underserved in terms of real, relatable entrepreneurial content, and The Founder’s Club aims to fill that gap.

Listeners can access Founder’s Club on all major podcast platforms, including Spotify, Apple Podcasts, and Google Podcasts. Each episode promises a captivating journey through entrepreneurial endeavours, providing both entertainment and education for listeners at any stage of their business journey.

Join the conversation and be part of a dynamic community that celebrates ambition, perseverance, and innovation. Subscribe to Founder’s Club podcast today and start your journey toward building a business that not only thrives but allows you to live a good life.

About Emily Jean:

Emily Jean is the founder of Live Good Digital, a trailblazing digital marketing agency, and now, the visionary behind the Founder’s Club Podcast. With a keen eye for digital trends and a passion for entrepreneurship, Jean is dedicated to guiding the next generation of business leaders toward success.

For more information, visit: www.livegooddigital.com/

Listen to the Podcast here: https://open.spotify.com/show/3kiqSke5mnlFIlC9t4xLU0?si=19b812aa43f442dc

And here:

https://podcasts.apple.com/us/podcast/founders-club/id1802430594

Media Contact
Company Name: Live Good Digital
Contact Person: Rita Williams
Email: Send Email
Country: Australia
Website: https://www.livegooddigital.com/

AutoInsuranceInSanAntonioTexas.com Launches New Platform to Simplify Auto Insurance Shopping for San Antonio Texas Drivers

SAN ANTONIO, Texas – March 25, 2025 – Auto Insurance In San Antonio Texas, a new online platform dedicated to helping San Antonio residents find suitable auto insurance coverage, officially launched its services today. The website aims to streamline the process of comparing and selecting car insurance policies by connecting consumers with multiple insurance providers in the San Antonio area.

With car insurance rates in San Antonio averaging $2,595 per year for full coverage, the need for an efficient way to compare options has never been greater. AutoInsuranceInSanAntonioTexas.com addresses this need by offering a user-friendly interface that allows drivers to input their information once and receive quotes from various insurers, potentially saving both time and money.

The platform takes into account San Antonio-specific factors that influence insurance rates, such as:

  • The city’s high accident rate, ranking second in Texas for total accidents

  • Recent increases in auto theft, with nearly 19,000 cars reported stolen in a 12-month period

  • Variations in premiums across different San Antonio zip codes

“Our goal is to empower San Antonio drivers with the information they need to make informed decisions about their auto insurance,” said john brown chief sales officer at AutoInsuranceInSanAntonioTexas.com. “By simplifying the comparison process, we hope to help residents find coverage that meets both their needs and budget.”

The website also provides educational resources to help users understand Texas auto insurance requirements, including the state-mandated 30/60/25 liability coverage. Additionally, it offers guidance on factors that can affect premiums, such as driving history, vehicle type, and available discounts.

AutoInsuranceInSanAntonioTexas.com is now live and available for San Antonio residents to use at no cost. 

For more information, visit https://autoinsuranceinsanantoniotexas.com

As part of its launch, AutoInsuranceInSanAntonioTexas.com is highlighting the importance of understanding insurance terminology and coverage options. For instance, many drivers may be unfamiliar with the meaning behind liability coverage limits such as $100k/$300k/$100k. This refers to coverage of up to $100,000 for bodily injury per person, $300,000 total for bodily injury per accident, and $100,000 for property damage per accident. By providing clear explanations and resources, the platform aims to demystify these concepts and help consumers make more informed decisions about their insurance needs.

The platform also addresses common questions about car insurance in San Antonio, such as who offers the cheapest rates and how much insurance typically costs. Currently, Texas Farm Bureau is often cited as one of the most affordable options for auto insurance in Texas, with rates averaging around $86 per month for full coverage. However, rates can vary significantly based on individual factors like driving history and vehicle type. By using AutoInsuranceInSanAntonioTexas.com, drivers can quickly compare quotes from multiple providers to find the best fit for their specific circumstances.

In addition to its core matching service, AutoInsuranceInSanAntonioTexas.com plans to expand its offerings with regular updates on insurance trends and tips for saving money on car insurance. This will include advice on how to take advantage of discounts for safe driving habits, insuring multiple vehicles, and bundling policies with other types of insurance like home insurance. By staying informed about these opportunities, San Antonio residents can potentially lower their insurance costs while maintaining comprehensive coverage. The website’s commitment to providing valuable insights and resources positions it as a trusted resource for anyone navigating the complex world of auto insurance in San Antonio.

Media Contact
Company Name: auto insurance in san antonio texas
Contact Person: John Brown
Email: Send Email
Country: United States
Website: https://autoinsuranceinsanantoniotexas.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AutoInsuranceInSanAntonioTexas.com Launches New Platform to Simplify Auto Insurance Shopping for San Antonio Texas Drivers

Urticaria Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Sanofi, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, Roche, Novartis, GSk

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Urticaria pipeline constitutes 20+ key companies continuously working towards developing 25+ Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Urticaria Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Urticaria Market.

 

The Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Urticaria Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Urticaria treatment therapies with a considerable amount of success over the years.

  • Urticaria companies working in the treatment market are Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others, are developing therapies for the Urticaria treatment

  • Emerging Urticaria therapies in the different phases of clinical trials are- Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others are expected to have a significant impact on the Urticaria market in the coming years.

  • In January 2025, Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell-driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, announced positive preliminary data from its ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adults with CSU. The study showed significant reductions in UAS7 scores, with an average change of -26.6 at eight weeks in the 240mg single-dose cohort, while multiple dosing regimens of 120mg or higher demonstrated UAS7 reductions exceeding -25 points. Clinical responses were observed as early as one week after the first dose, with some patients achieving Complete Responses (UAS7 = 0) at all therapeutic dose levels (80mg, 120mg, 180mg, and 240mg). Notably, all patients in the 240mg single-dose cohort (N=3) maintained Complete Responses through the eight-week period.

  • In September 2024, Regeneron Pharmaceuticals and Sanofi reported that the confirmatory Phase III trial (LIBERTY-CUPID Study C) for Dupixent (dupilumab) successfully achieved its primary and key secondary endpoints. The study evaluated Dupixent as an investigational treatment for patients with uncontrolled, biologic-naïve chronic spontaneous urticaria (CSU) who were also receiving background antihistamine therapy.

  • In September 2024, Evommune announced that the first patient has been enrolled in a Phase II clinical trial evaluating EVO756 in adults with CIndU.

  • In June 2024, Celldex Therapeutics reported data showing that barzolvolimab significantly improves angioedema at 12 weeks in its Phase II clinical trial for chronic spontaneous urticaria (CSU).

  • In May 2024, Novartis released new data confirming the long-term efficacy and safety of remibrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, for chronic spontaneous urticaria (CSU).

  • In March 2024, Jasper Therapeutics announced that the first patient has been dosed in its Phase Ib/IIa (SPOTLIGHT) clinical trial evaluating subcutaneous briquilimab for the treatment of CIndU.

  • In February 2024, ARS Pharmaceuticals reported positive efficacy results from its Phase II inpatient study evaluating neffy (epinephrine nasal spray), an investigational drug, for chronic spontaneous urticaria.

 

Urticaria Overview

Urticaria, commonly known as hives, is a skin condition characterized by the sudden appearance of red, itchy welts or wheals on the skin. These welts can vary in size and shape, often merging together to form larger areas of raised skin. Urticaria can be acute, lasting less than six weeks, or chronic, persisting for more than six weeks.

 

Get a Free Sample PDF Report to know more about Urticaria Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/urticaria-pipeline-insight

 

Emerging Urticaria Drugs Under Different Phases of Clinical Development Include:

  • Ligelizumab: Novartis

  • Remibrutinib (LOU064): Novartis

  • Tezepelumab: Amgen

  • CDX-0159: Celldex Therapeutics

  • GI-301: GI Innovation

  • Dupilumab (DUPIXENT): Sanofi/ Regeneron

  • UB-221: United BioPharma

  • MTPS9579A: Genentech

  • Lirentelimab (AK002): Allakos Inc.

  • TAS5315: Taiho Pharma

  • rilzabrutinib: Sanofi

  • GDC-0853: Genentech, Inc.

  • AZD1981: AstraZeneca

  • Desloratadine: Organon and Co

 

Urticaria Route of Administration

Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Urticaria Molecule Type

Urticaria Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Urticaria Pipeline Therapeutics Assessment

  • Urticaria Assessment by Product Type

  • Urticaria By Stage and Product Type

  • Urticaria Assessment by Route of Administration

  • Urticaria By Stage and Route of Administration

  • Urticaria Assessment by Molecule Type

  • Urticaria by Stage and Molecule Type

 

DelveInsight’s Urticaria Report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Urticaria product details are provided in the report. Download the Urticaria pipeline report to learn more about the emerging Urticaria therapies

 

Some of the key companies in the Urticaria Therapeutics Market include:

Key companies developing therapies for Urticaria are – Sanofi, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, Roche, Novartis, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.

 

Urticaria Pipeline Analysis:

The Urticaria pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Urticaria with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Urticaria Treatment.

  • Urticaria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Urticaria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Urticaria drugs and therapies

 

Urticaria Pipeline Market Drivers

  • Treatment Side Effects with Currently Available Treatment, Economic Burden on Patients, Increase in Research and Development Activities, Increasing Market Size, are some of the important factors that are fueling the Urticaria Market.

 

Urticaria Pipeline Market Barriers

  • However, Lack of Understanding of Disease Pathology, Approaching Patent Cliff, and other factors are creating obstacles in the Urticaria Market growth.

 

Scope of Urticaria Pipeline Drug Insight

  • Coverage: Global

  • Key Urticaria Companies: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others

  • Key Urticaria Therapies: Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others

  • Urticaria Therapeutic Assessment: Urticaria current marketed and Urticaria emerging therapies

  • Urticaria Market Dynamics: Urticaria market drivers and Urticaria market barriers

 

Request for Sample PDF Report for Urticaria Pipeline Assessment and clinical trials

 

Table of Contents

1. Urticaria Report Introduction

2. Urticaria Executive Summary

3. Urticaria Overview

4. Urticaria- Analytical Perspective In-depth Commercial Assessment

5. Urticaria Pipeline Therapeutics

6. Urticaria Late Stage Products (Phase II/III)

7. Urticaria Mid Stage Products (Phase II)

8. Urticaria Early Stage Products (Phase I)

9. Urticaria Preclinical Stage Products

10. Urticaria Therapeutics Assessment

11. Urticaria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Urticaria Key Companies

14. Urticaria Key Products

15. Urticaria Unmet Needs

16 . Urticaria Market Drivers and Barriers

17. Urticaria Future Perspectives and Conclusion

18. Urticaria Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Urticaria Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Sanofi, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, Roche, Novartis, GSk